2-HG levels in IDH-mutant and IDH-wild-type samples. 2-HG measurements in samples from patients with a wild-type-IDH1/2 (n = 33) versus those harboring IDH1/2-mutations (n = 9), obtained at presentation, showing 2-HG measurement in serum (A), urine (B), myeloblasts (C), and marrow aspirate (D). Each point represents an individual patient sample; blue dots represent IDH-wild-type samples; and red dots, IDH-mutant samples. The left column in each figure represents the wild-type samples; and the right column, the mutant samples. In each column, horizontal bars represent the median; and vertical lines, the lower and upper quartiles. (A,C) Dotted line across graphs indicates 2HG levels of 1000 ng/mL serum or 1000 ng/2 × 10⁶ within cells, respectively, above which 2-HG levels were deemed to be elevated in this study. All figures describe a statistically significant difference in 2-HG levels between IDH1/2-mutant samples relative to wild-type samples (P < .05). One IDH-mutant patient did not have elevated baseline serum levels of 2-HG but did demonstrate elevated myeloblast 2-HG at baseline.